相关实验视频

Updated: May 30, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

在低PD-L1表达的非性非小细胞肺癌中选择化学免疫治疗方案:多中心回顾性队列研究

Tae Hata¹, Tadaaki Yamada¹, Yasuhiro Goto²

¹Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Clinical lung cancer

|January 26, 2025

概括

晚期非小细胞肺癌 (NSCLC) 的化学免疫疗法,PD-L1表达低,在治疗方案中显示出相似的生存率. 抗PD-L1组合化疗可以降低严重肺炎的风险,提供更安全的治疗选择.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
肺部病理学肺部病理学

背景情况:

化疗免疫疗法是高级非状NSCLC与低PD-L1表达的标准.
在这组患者中,不同免疫检查点抑制剂 (ICI) 之间没有直接比较.
这项研究解决了基于证据的治疗指导的需要.

研究的目的:

为了比较不同ICI化疗方案的疗效和安全性.
为了指导晚期非皮性NSCLC的治疗决策,PD-L1表达率在1%至49%之间.

主要方法:

对316名患有晚期非皮层性NSCLC和PD-L1 TPS 1-49%的患者进行了回顾性分析.
患者接受了基于的化疗,并与抗PD-1,抗PD-L1或抗PD-1/CTLA-4抗体相结合.
对生存结果和≥3级不良事件的比较.

主要成果:

没有观察到中位总生存时间 (28.6 vs 23.1 vs 24.4 个月) 或无进展生存时间 (9.4 vs 7.2 vs 8.7 个月) 的显著差异.
抗PD-1/CTLA-4/化疗组的血液毒性较低,但非血液毒性较高.
抗PD-L1/化疗组的肺炎发病率显著降低≥3级 (P = .049).

结论:

在评估的化学免疫疗法方案中,生存结果是可比的.
治疗组之间的不良事件概况显著不同.
在这种患者群体中,抗PD-L1抗体组合化疗可能与严重肺炎的风险降低有关.

关键词:

化疗化疗是一种化学疗法.免疫检查点抑制剂免疫检查点抑制剂肺炎是一种肺炎.饮食方式饮食方式生存结果的结果.

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...